Scotiabank analyst Greg Harrison raised the firm’s price target on Disc Medicine (IRON) to $75 from $73 and keeps an Outperform rating on the shares. The accelerated path to approval for bitopertin is in sight, with the company targeting NDA submission in erythropoietic protoporphyria in 2H of 2025, the analyst tells investors. The firm views accelerated approval de-risked since bitopertin has shown clinically meaningful reductions in protoporphyrin IX. Additionally, the company’s cash position has strengthened, with runway now expected into 2028, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine’s Strategic Advancements and Promising Pipeline Drive Buy Rating
- Promising Prospects for Disc Medicine: Buy Rating Backed by Bitopertin’s Potential and Strong Financial Health
- Disc Medicine’s 2024 Financial Results and Clinical Progress
- Disc Medicine: Strong Financial and Clinical Position Supports Buy Rating
- Nvidia, Constellation Brands downgraded: Wall Street’s top analyst calls